Cancer treatment effective for managing diabetes-related edema and cataract surgeryThe journal Ophthalmology has reported on use of bevacizumab (Avastin) for providing relief to patients with macular edema and individuals with cystoid macular edema after cataract surgery.

Another study has described methods for enhancing the level of safety to make cataract surgery safer for diabetic retinopathy (DR) patients.

It is believed that diabetic retinopathy would be one of the greatest threats in the coming future with predictions for triple growth in such cases by the year 2050.

As per the Pan-American Collaborative Retina Study Group, led by J. Fernando Arevalo, MD, of the Caracas Central Ophthalmologic Clinic, Venezuela, treating DMME (diffused macular edema) with bevacizumab (Avastin), an anti-vascular endothelial growth factor (anti-VEGF) medication, is a better option though future studies in this regard to confirm efficacy and safety in treating these conditions.